Is NBIX a good stock to buy?
We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro’s Substack
In this article, we will summarize the bulls’ thesis on NBIX. Neurocrine Biosciences, Inc.’s share was trading at $159.76 as of June 12th. NBIX’s trailing and forward P/E were 24.58 and 22.57 respectively according to Yahoo Finance.
Likoper/ Neurocrine Biosciences, Inc. (NBIX) is a San Diego-based biopharmaceutical company focused on central nervous system, neurological, psychiatric, and endocrine disorders, positioned to benefit from rising demand in central nervous system therapeutics as aging populations and broader insurance coverage expand diagnosis and treatment of brain-related conditions. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Neurocrine Biosciences’ flagship therapy Ingrezza (valbenazine), a treatment for tardive dyskinesia, continues to anchor growth, with significant room for expansion as many eligible patients remain untreated and prescription penetration increases across the U.S. psychiatric care system. Momentum is supported by successful launch of Crenessity (crinecerfont) for congenital adrenal hyperplasia, adding diversification beyond its core neurology franchise. Importantly, Neurocrine Biosciences is advancing late-stage pipeline programs, including Phase 3 (Phase 3 clinical trials) candidates in major depressive disorder and schizophrenia, large underserved markets with meaningful commercial upside if successfully developed and approved.